All News

This study demonstrates the feasibility and impact of a pharmacist-led direct challenge approach to penicillin allergy delabeling in a community hospital setting.

The 2025 International Myeloma Society Annual Meeting unveils crucial updates to IMWG guidelines, enhancing response assessment and treatment strategies for multiple myeloma.

A recent study highlights the AOV dual-chamber system as a faster, safer option for RSV vaccine reconstitution, enhancing efficiency for health care providers.

Misinformation is fueling parental fears and a concerning drop in childhood vaccines.

Engagement and recognition of pharmacist expertise grows as state psychedelic bills expand.

Breast cancer survivors face a small but significant risk of developing secondary cancers, influenced by age, treatment, and lifestyle factors.

Promising phase 2 results for taletrectinib in ROS1+ lung cancer show significant tumor shrinkage and manageable adverse effects.

Digitoxin reduces primary composite vs placebo in HFrEF, with no statistically significant effect on individual components of all-cause mortality or first heart failure-related hospitalization.

A recent phase 3 study reveals osimertinib combined with chemotherapy offers unprecedented survival rates for patients with advanced EGFR-mutated lung cancer.

Cutting-edge insights and expert discussions on multiple myeloma will be presented at the 2025 IMS Annual Meeting in Toronto, shaping future treatment standards.

A series of PCSK9 inhibitors were found to be tolerable and effective at reducing low-density lipoprotein cholesterol in solid organ transplant recipients.

In a recent study, machine learning demonstrated its ability to predict progression to end-stage renal disease among patients with chronic kidney disease (CKD).

Pharmacists face challenges as recent federal policy changes threaten their expanded roles in vaccination and public health, impacting patient access to care.

GLP-1 receptor agonists enhance glycemic control and weight management in youth with type 2 diabetes (T2D) and obesity; however, safety concerns persist.

World Lymphoma Day highlights the rising prevalence of lymphoma and innovative treatments, emphasizing the role of pharmacists in patient care.

Research reveals that this population may experience lower short-term mortality rates after major surgery, challenging traditional BMI guidelines.

Use of educational resources at a gastrointestinal office improved pneumococcal vaccine uptake in patients with celiac disease.

Crystal Hodge, PharmD, BCIDP, BCPS, discusses a 3-pronged approach—isolating, vaccinating, and educating—to help pharmacists manage respiratory virus season and routine immunizations like MMR.

When combined with an anti–PD-L1 therapy, tarlatamab significantly improves overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

Abdulwhab Shremo Msdi, PharmD, BCIDP, advances research in infectious diseases and microbiome-related conditions.

Explore insights into ongoing tensions in the pharmacy industry and their potential impact on competition.

New FDA regulations are intended to enhance transparency in prescription drug advertising, empowering pharmacists to educate patients on medication risks and benefits.

Research reveals semaglutide's potential to reduce cocaine-seeking behavior in rats, suggesting a promising avenue for treating cocaine dependency in humans.

In STRIDE-13, the pneumococcal 21-valent conjugate vaccine (PCV21) induced robust immunogenicity in young, high-risk individuals against invasive pneumococcal disease.

Pharmacists enhance patient safety by addressing common medication errors, ensuring proper drug use, and improving therapeutic outcomes in clinical practice.

A fatal pediatric measles case in Los Angeles highlights the urgent need for MMR vaccination to protect vulnerable children from severe complications.

Recaticimab significantly lowered low-density lipoprotein cholesterol (LDL-C) levels, showing promise in becoming a future proprotein convertase subtilisin/kexin type 9 (PCSK9) option for cholesterol reduction.

Investigators from the phase 3 COAST 1 trial demonstrated the efficacy and safety of amlitelimab in patients with moderate-to-severe atopic dermatitis.